Otsuka Holdings Co., Ltd. 4578
TSE · Japan · Health Technology
¥11,465.00-120.00 (-1.04%)
Market closed· · JPY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · JPY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Vera Therapeutics takes a step toward securing full Food and Drug Administration approval for its injectable kidney drug, Trutakna.
If you are looking for stocks that are well positioned to maintain their recent uptrend, Otsuka Holdings Co., Ltd. - Unsponsored ADR (OTSKY) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
DelveInsight's Underactive Bladder Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, underactive bladder syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, Japan, and China].
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.